Summary
p53 and Bcl-2 are two important factors related to apoptosis and tumorigenesis. In this study, a series of 52 cases of pancreatic carcinoma (PC) were investigated using an immunohistochemical assay to determine whether altered expression of Bcl-2 and p53 has an impact on the progression of this malignancy. Cytoplasmic immunoreactivity for Bcl-2 and nuclear staining of p53 was found in 12 (23.1%) and 32 (63.5%) cases of PC respectively. Furthermore, an inverse correlation between the expression of p53 and Bcl-2 existed in this series (P < 0.01). In a subgroup, the proportion of tumours showing that p53-positive and Bcl-2-negative staining was increased with increasing histological grade and clinical stage (P < 0.05), and moreover, the survival period of those patients whose tumour had this staining was shorter than those with other staining patterns of combined p53 and Bcl-2 (P < 0.05). Therefore, it is concluded that simultaneously aberrant expression of Bcl-2 and p53 may confer PC with more malignant clinicopathological characteristics.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aizawa, S., Sasaki, M., Wada, R. I., Koyama, M. & Yagihashi, S. (1996). p53 protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis. J Surg Oncol 62: 279–283.
Barton, C. M., Staddon, S. L., Hughes, C. M., Hall, P. A., O’Sullivan, C. & Klöppel, G. (1991). Abnormalilities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 64: 1076–1082.
Cordon-Cardo, C., Dalbagni, D., Saez, G., Oliva, M. R., Zhang, Z. F., Rosai, J., Reuter, V. E. & Pellicer, A. (1994). TB53 muations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347–353.
Dameron, K. M., Volpert, O. G., Tainsky, M. A. & Buck, N. (1994). Control of angiogenesis in fibroblast by p53 regulation of thrombospondin. Science 265: 1582–1584.
Fontanini, G., Vignati, S., Lucchi, M., Mussi, A., Calcinai, A., Boldrimi, L., Chine, S., Silverstri, V., Angelletti, C. A., Basolo, F. & Bevilacqua, G. (1997). Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 75: 1295–1301.
Haldar, S., Negrini, M., Monne, M., Sabbioni, S. & Croce, C. M. (1994). Down-regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095–2057.
Hermreck, A. S., Thomas, C. O. Y. & Friezes, S. R. (1974). Importance of pathologic staging in the surgical management of adenocarcinoma of the exocrine pancreas. Am J Surg 85: 653–657.
Hurlimann, J., Larrinaga, B. & Vala, D. L. (1995). bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 426: 163–168.
Ishida, H., Irie, K., Itoh, T., Furkukawa, T. & Tokunaga, O. (1997). The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 80: 1034–1045.
Kieser, A., Weich, H. A., Brandner, G., Marmé, D. & Kolch, W. (1994). Mutant p53 potentiates protein kinase C introduction of vascular endothelial growth factor expression. Oncogene 9: 964–969.
Klöppel, G., Lingenthal, G., Vonbülow, M. & Kern, H. F. (1985). Histological and fine structural features of pancreatic ductal adenocarcinoma in relation to growth and prognosis: studies in xenografted tumors and clinicopathological correlation in a series of 75 cases. Histopathology 9: 841–856.
Krajewski, S., Krajewska, M., Shabaik, A., Miyashita, T., Wang, H-G & Reed, J. C. (1994). Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 145: 1323–1333.
Krajewski, S., Thor, A. D., Edgerton, S. M., Moore, D. H., Krajewska, M. & Reed, J. C. (1997). Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 3: 199–208.
Lundin, J., Nordling, S., von Boguslawsky, K., Roberts, P. J. & Haglund, C. (1996). Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 53: 104–111.
McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsiek, J. T., Tu, S. M. & Campbell, M. L. (1992). Expression of prooncogene Bcl-2 in the prostate and its associated with emergence of androgen-independent prostate cancer. Cancer 52: 6940–6947.
Miyashita, T., Harigai, M., Hanada, M. & Reed, J. C. (1994). Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131–3135.
Nakamura, S., Akazawa, N., Yao, T. & Tsuneyoshi, M. (1996). Inverse correlation between the expression of bcl-2 and p53 protein in primary gastric lymphoma. Hum Pathol 27: 225–233.
Ohbu, M., Saegusa, M., Kobayashi, N., Tsukamoto, H., Mieno, H., Kakita, A. & Okayasu, I. (1997). Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer 79: 1287–1293.
Pezzella, F., Turley, H., Kuzu, I., Tungekar, F. M., Dunnil, S. M. & Pierce, C. B. (1993). bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690–694.
Piris, M. A., Pezzella, F., Martinez-Montero, J. C., Orradre, J. L., Villuendas, R., Sanchez-Beato, M., Cuena, R., Cruz, M. A. & Martinez, B. (1994). p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69: 337–341.
Ruggeri, B. A., Huang, L., Berger, D., Chang, H., Klein-Szanto, A. J. P., Goodrow, T., Wood, M., Obara, Y., Heath, C. W. & Lynch, H. (1997). Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer 79: 700–716.
Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J. & Takahashi, H. (1997). Expression of Fas ligand in liver metastases of human colonic adenocarcinoma. Proc Natl Acad Sci USA 94: 6420–6425.
Sinicrope, F. A., Evans, D. B., Leach, S. D., Cleary, K. R., Fenoglio, C. J., Lee, J. J. & Abbruzzese, J. L. (1996). bcl-2 and p53 expression in respectable pancreatic adenocarcinoma: associated with clinical outcome. Clin Cancer Res 2: 2015–2022.
Stattin, P., Damber, J. E., Karlberg, L., Nordgren, H. & Bergh, A. (1996). Bcl-2 immuno-reactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 24: 257–264.
Tjalma, W., Weyler, J., Goovaerts, G., De-Pooter, C., Van-Marck, E. & van-Dam, P. (1997). Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix. J Clin Pathol 50: 33–36.
Tron, V. A., Krajewski, S., Klein-Parker, H., Li, G. & Reed, J. C. (1995). Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 146: 643–650.
Yamanaka, Y., Friess, H., Buvhler, M., Beger, H. G., Uchida, E., Onda, M., Kobin, M. S. & Konc, M. (1993). Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 53: 5289–5296.
Yan, J-J, Chen, F-F & Jin, Y-T (1996). Immmunohistochemical detection of Bcl-2 protein in small cell lung carcinomas. Oncology 53: 6–11.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hu, YX., Watanabe, H., Ohtsubo, K. et al. Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br J Cancer 80, 1075–1079 (1999). https://doi.org/10.1038/sj.bjc.6690466
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690466
Keywords
This article is cited by
-
Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
British Journal of Cancer (2011)
